Brief: Tot Biopharm International Says Unit Received Approval Of Its Supplemental Application For New Indications Of Bevacizumab Injection
09/03/2022 10:43
March 9 (Reuters) - TOT BIOPHARM International:
* UNIT RECEIVED APPROVAL OF ITS SUPPLEMENTAL APPLICATION
FOR NEW
INDICATIONS OF BEVACIZUMAB INJECTION ISSUED BY NMPA
Source text for Eikon: ID:nHKS2W5qNm
Further company coverage: 1875.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioDlink International
See all newsCorrected: China's BioDlink International HY revenue falls (September 29)
Brief: Biodlink International To Deliver Ten Batches Of Monoclonal Antibody Intermediates To Wuxi Biologics
Brief: Biodlink International Says Shan Fu Resigns As Executive Director And Chairperson
Brief: BioDlink International Says WuXi XDC Cayman To Make Conditional Cash Offer For All Co Shares
Brief: HKEX Says Trading In Shares Of Biodlink International Will Be Halted At Dec 29